Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults

Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults

BackgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is presently the most prevalent chronic liver disorder globally that is closely linked to obesity, dyslipidemia metabolic syndrome, and type 2 diabetes mellitus (T2DM). Its pathogenesis is strongly associated with inflammation, a...

Full description

Bibliographic Details
Main Authors:	Jing Yan, Jun Zhou, Yuanyuan Ding, Chuantao Tu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-03-01
Series:	Frontiers in Nutrition
Subjects:	metabolic dysfunction-associated fatty liver disease dietary inflammatory index dietary quality NHANES steatotic liver disease disease progression
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2024.1340453/full

Similar Items

Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003–2018
by: Jie Pan, et al.
Published: (2023-09-01)

Association of energy-adjusted dietary inflammatory index and frailty in older adults with nonalcoholic fatty liver disease
by: Lin Shi
Published: (2023-10-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases
by: Madan Kumar Arumugam, et al.
Published: (2023-10-01)

Association of Dietary Acid Load with Nonalcoholic Fatty Liver Disease and Advanced Liver Fibrosis in US Adults: Evidence from NHANES 1999–2018
by: Cheng J, et al.
Published: (2023-12-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
by: Tsubasa Tsutsumi, et al.
Published: (2024-04-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
by: Wayne Eskridge, et al.
Published: (2023-09-01)

Dietary inflammatory index and risk of non-alcoholic fatty liver disease and advanced hepatic fibrosis in US adults
by: Zhongmian Zhang, et al.
Published: (2023-01-01)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
by: Nan Yao, et al.
Published: (2022-06-01)

New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score
by: Lei Peng, et al.
Published: (2024-01-01)

Analysis of the association between dietary patterns and nonalcoholic fatty liver disease in a county in Guangxi
by: Song Xiao, et al.
Published: (2023-09-01)

The relationship between vitamin K and metabolic dysfunction-associated fatty liver disease among the United States population: National Health and Nutrition Examination Survey 2017–2018
by: Xinyue Wang, et al.
Published: (2023-04-01)

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Avneet Singh, et al.
Published: (2024-02-01)

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence
by: Jingli Gao, et al.
Published: (2024-03-01)

The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Jaejun Lee, et al.
Published: (2024-02-01)

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside
by: Pojsakorn Danpanichkul, et al.
Published: (2024-01-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study
by: Michihiro Iwaki, et al.
Published: (2024-04-01)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort studyResearch in context
by: Joon Ho Moon, et al.
Published: (2023-11-01)

Association between diet soft drink consumption and metabolic dysfunction-associated steatotic liver disease: findings from the NHANES
by: Yanrui Wu, et al.
Published: (2023-11-01)

The association of dietary phytochemical index and nonalcoholic fatty liver disease
by: Bijan Ahmadi, et al.
Published: (2023-07-01)

Dietary advanced glycation end products are associated with an increased risk of non-alcoholic fatty liver disease in Iranian adults
by: Mitra Kazemi Jahromi, et al.
Published: (2023-05-01)

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
by: Yumin Wang, et al.
Published: (2024-01-01)

Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Dietary inflammatory index (DII) is correlated with the incidence of non-alcoholic fatty liver disease (NAFLD): Fasa PERSIAN cohort study
by: Adib Valibeygi, et al.
Published: (2023-07-01)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
by: Hidekatsu Yanai, et al.
Published: (2023-10-01)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
by: Yunqian Huang, et al.
Published: (2023-11-01)

Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
by: Zhenmin Liu, et al.
Published: (2024-03-01)

Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
by: Miren García-Cortés, et al.
Published: (2023-12-01)

Role of the co-stimulatory molecule inducible T-cell co-stimulator ligand (ICOSL) in the progression of experimental metabolic dysfunction-associated steatohepatitis
by: Alessia Provera, et al.
Published: (2023-11-01)

The association between the dietary inflammatory index (DII) and some serum oxidative stress markers in Non-Alcoholic fatty liver disease: Case- control
by: Fateme Moradi, et al.
Published: (2022-01-01)

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
by: Guocheng Rao, et al.
Published: (2023-11-01)

2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
by: Amélio F. Godoy-Matos, et al.
Published: (2024-01-01)

Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
by: Rodrigo Oliveira Moreira, et al.
Published: (2023-12-01)

Association between dietary inflammatory index and atherosclerosis cardiovascular disease in U.S. adults
by: Jie Zhang, et al.
Published: (2023-01-01)

Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores
by: Tiago Lima Capela, et al.
Published: (2023-12-01)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01)

Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
by: Koki Nagai, et al.
Published: (2023-10-01)

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
by: Zehra N. Kocas-Kilicarslan, et al.
Published: (2024-01-01)